WestHolland Foreign Investment Agency (WFIA) WFIA is quite a remarkable organisation that has been, since its inception ten years ago, reporting very good results. The annual results last week showed another strong focus on the Life Sciences sector. What drives the agency to place so much effort on attracting investments in Life Sciences in the…
Cegedim Dentrite Italy Ten years of experience in the Dendrite group enabled you to cover a number of international positions, before its acquisition by Cegedim in May 2007. How has the integration progressed at the time, and what has this strategic acquisition meant for Dendrite in Italy? Entering the Italian team coming from…
Boehringer Ingelheim Brazil You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three years, my assignment was to open this company and to integrate it more with Brazil. We have a quite enlightened…
Celgene Hungary The Hungarian pharmaceutical environment has been undergoing a turbulent time recently, with many new measures being implement by the Government. What are your observations, and how do you expect companies to be adjusting their strategies in this market? The government has a large majority in the parliament since 2 years,…
Boehringer Ingelheim B.V. While already having worked for Boehringer Ingelheim for quite some time, the end of 2010 marked the completion of your first full year as general manager of this Dutch affiliate. What were some of the highlights of the past year and the main lessons that you look forward to carrying…
Boehringer Ingelheim Italy The main distinctive point of Boehringer Ingelheim Italy within the group is its business structure, which relies on three different units: Boehringer Ingelheim Spa, Bidachem and Istituto de Angeli. Could you describe the role of each entity together with its contribution to resources and growth? Boehringer Ingelheim itself is responsible…
Dr Reddy's Laboratories Looking back at the company’s recent challenges, we see a very tough 2009, largely due to the Betapharm acquisition and the subsequent changes in German regulations. How do you explain the situation there and what measures did you take to turn the situation around? Germany, and in particular the Betapharm…
India Dilip Surana of family-run Indian generics giant Micro Labs talks company performance, the evolution of the Indian pharma market, and strategy moving forward. Last year Micro Labs moved up in the rankings. How satisfied are you with the company’s performance in 2010? The company performed satisfactorily last year, showing good…
Gedeon Richter Czech Republic Mr. Gyürüsi, Gedeon Richter is a 111-year-old company that is synonymous with the Central and Eastern European pharma industry. The business has been present in Czechoslovakia since 1956, and has acted independently in the Czech Republic since 1992. Can you give our readers a more detailed idea of the history…
Genzyme Poland With the current acquisition of Genzyme by Sanofi-Aventis, the French giant is planning to have Genzyme as a centre of excellence for rare diseases. Genzyme operates in the genetic market, in bio-surgery, in oncology, and also in transplant. What area has been driving the growth in 2010? In value terms,…
Novartis Argentina When we met with Javier Lombar at IMS Argentina, he was explaining how a lot of multinational companies are using Argentina as a regional base of operations. Novartis is a prime example of this. Could you explain how Novartis operates in a Latin American context, and what role the Argentinean…
See our Cookie Privacy Policy Here
